Literature DB >> 30561539

Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.

Jean Claude Dejon-Agobe1, Ulysse Ateba-Ngoa1,2,3, Albert Lalremruata2, Andreas Homoet1, Julie Engelhorn1, Odilon Paterne Nouatin1, Jean Ronald Edoa1, José F Fernandes1,2, Meral Esen1,2, Yoanne Darelle Mouwenda1,3, Eunice M Betouke Ongwe1, Marguerite Massinga-Loembe1,2, Stephen L Hoffman4, B Kim Lee Sim4, Michael Theisen5,6,7, Peter G Kremsner1,2, Ayôla A Adegnika1,2,3, Bertrand Lell1,2, Benjamin Mordmüller1,2.   

Abstract

BACKGROUND: GMZ2 is a recombinant malaria vaccine inducing immune responses against Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We used standardized controlled human malaria infection (CHMI) to assess the efficacy of this asexual blood-stage vaccine.
METHODS: We vaccinated 50 healthy, adult volunteers with lifelong exposure to Pf 3 times, at 4-week intervals, with 30 or 100 µg GMZ2 formulated in CAF01, a liposome-based adjuvant; 100 µg GMZ2, formulated in Alhydrogel; or a control vaccine (Verorab). Approximately 13 weeks after the last vaccination, 35/50 volunteers underwent CHMI by direct venous inoculation of 3200 Pf sporozoites (Sanaria® PfSPZ Challenge).
RESULTS: Adverse events were similarly distributed between GMZ2 and control vaccinees. Baseline-corrected anti-GMZ2 antibody concentrations 4 weeks after the last vaccination were higher in all 3 GMZ2-vaccinated arms, compared to the control group. All GMZ2 formulations induced similar antibody levels. CHMI resulted in 29/34 (85%) volunteers with Pf parasitemia and 15/34 (44%) with malaria (parasitemia and symptoms). The proportion of participants with malaria (2/5 control, 6/10 GMZ2-Alhydrogel, 2/8 30 µg GMZ2-CAF01, and 5/11 100 µg GMZ2-CAF01) and the time it took them to develop malaria were similar in all groups. Baseline, vaccine-specific antibody concentrations were associated with protection against malaria.
CONCLUSIONS: GMZ2 is well tolerated and immunogenic in lifelong-Pf-exposed adults from Gabon, with similar antibody responses regardless of formulation. CHMI showed no protective effect of prior vaccination with GMZ2, although baseline, vaccine-specific antibody concentrations were associated with protection. CHMI with the PfSPZ Challenge is a potent new tool to validate asexual, blood-stage malaria vaccines in Africa. CLINICAL TRIALS REGISTRATION: Pan-African Clinical Trials: PACTR201503001038304.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Plasmodium falciparumzzm321990 ; clinical trial; controlled human malaria infection; malaria vaccine

Year:  2019        PMID: 30561539      PMCID: PMC6763635          DOI: 10.1093/cid/ciy1087

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

1.  Prospective Clinical Trial Assessing Species-Specific Efficacy of Artemether-Lumefantrine for the Treatment of Plasmodium malariae, Plasmodium ovale, and Mixed Plasmodium Malaria in Gabon.

Authors:  Mirjam Groger; Luzia Veletzky; Albert Lalremruata; Chiara Cattaneo; Johannes Mischlinger; Rella Zoleko-Manego; Lilian Endamne; Anna Klicpera; Johanna Kim; The Nguyen; Lena Flohr; Jonathan Remppis; Pierre-Blaise Matsiegui; Ayôla A Adegnika; Selidji T Agnandji; Peter G Kremsner; Benjamin Mordmüller; Ghyslain Mombo-Ngoma; Michael Ramharter
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Protection against malaria by MSP3 candidate vaccine.

Authors:  Sodiomon B Sirima; Simon Cousens; Pierre Druilhe
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

3.  A field trial to assess a blood-stage malaria vaccine.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Amed Ouattara; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Idrissa Traore; Bourema Kouriba; Dapa A Diallo; Issa Diarra; Modibo Daou; Amagana Dolo; Youssouf Tolo; Mahamadou S Sissoko; Amadou Niangaly; Mady Sissoko; Shannon Takala-Harrison; Kirsten E Lyke; Yukun Wu; William C Blackwelder; Olivier Godeaux; Johan Vekemans; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

4.  Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.

Authors:  Kirsten E Lyke; Andrew S Ishizuka; Andrea A Berry; Sumana Chakravarty; Adam DeZure; Mary E Enama; Eric R James; Peter F Billingsley; Anusha Gunasekera; Anita Manoj; Minglin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Natasha Kc; Tooba Murshedkar; Floreliz H Mendoza; Ingelise J Gordon; Kathryn L Zephir; LaSonji A Holman; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Jamie G Saunders; Nina M Berkowitz; Barbara J Flynn; Martha C Nason; Lindsay S Garver; Matthew B Laurens; Christopher V Plowe; Thomas L Richie; Barney S Graham; Mario Roederer; B Kim Lee Sim; Julie E Ledgerwood; Stephen L Hoffman; Robert A Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

5.  Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.

Authors:  David J Pombo; Gregor Lawrence; Chakrit Hirunpetcharat; Christine Rzepczyk; Michelle Bryden; Nicole Cloonan; Karen Anderson; Yuvadee Mahakunkijcharoen; Laura B Martin; Danny Wilson; Salenna Elliott; Suzanne Elliott; Damon P Eisen; J Brice Weinberg; Allan Saul; Michael F Good
Journal:  Lancet       Date:  2002-08-24       Impact factor: 79.321

6.  Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.

Authors:  Robert A Seder; Lee-Jah Chang; Mary E Enama; Kathryn L Zephir; Uzma N Sarwar; Ingelise J Gordon; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Adam Richman; Sumana Chakravarty; Anita Manoj; Soundarapandian Velmurugan; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Floreliz H Mendoza; Jamie G Saunders; Martha C Nason; Jason H Richardson; Jittawadee Murphy; Silas A Davidson; Thomas L Richie; Martha Sedegah; Awalludin Sutamihardja; Gary A Fahle; Kirsten E Lyke; Matthew B Laurens; Mario Roederer; Kavita Tewari; Judith E Epstein; B Kim Lee Sim; Julie E Ledgerwood; Barney S Graham; Stephen L Hoffman
Journal:  Science       Date:  2013-08-08       Impact factor: 47.728

7.  Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.

Authors:  Benjamin Mordmüller; Güzin Surat; Heimo Lagler; Sumana Chakravarty; Andrew S Ishizuka; Albert Lalremruata; Markus Gmeiner; Joseph J Campo; Meral Esen; Adam J Ruben; Jana Held; Carlos Lamsfus Calle; Juliana B Mengue; Tamirat Gebru; Javier Ibáñez; Mihály Sulyok; Eric R James; Peter F Billingsley; K C Natasha; Anita Manoj; Tooba Murshedkar; Anusha Gunasekera; Abraham G Eappen; Tao Li; Richard E Stafford; Minglin Li; Phil L Felgner; Robert A Seder; Thomas L Richie; B Kim Lee Sim; Stephen L Hoffman; Peter G Kremsner
Journal:  Nature       Date:  2017-02-15       Impact factor: 49.962

8.  Diagnosis and treatment based on quantitative PCR after controlled human malaria infection.

Authors:  Jona Walk; Remko Schats; Marijke C C Langenberg; Isaie J Reuling; Karina Teelen; Meta Roestenberg; Cornelus C Hermsen; Leo G Visser; Robert W Sauerwein
Journal:  Malar J       Date:  2016-08-05       Impact factor: 2.979

9.  Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Authors:  Victorine A Mensah; Aly Gueye; Magatte Ndiaye; Nick J Edwards; Danny Wright; Nicholas A Anagnostou; Massamba Syll; Amy Ndaw; Annie Abiola; Carly Bliss; Jules-François Gomis; Ines Petersen; Caroline Ogwang; Tandakha Dieye; Nicola K Viebig; Alison M Lawrie; Rachel Roberts; Alfredo Nicosia; Babacar Faye; Oumar Gaye; Odile Leroy; Egeruan B Imoukhuede; Katie J Ewer; Philip Bejon; Adrian V S Hill; Badara Cisse
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

10.  Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.

Authors:  Nirianne Marie Q Palacpac; Edward Ntege; Adoke Yeka; Betty Balikagala; Nahoko Suzuki; Hiroki Shirai; Masanori Yagi; Kazuya Ito; Wakaba Fukushima; Yoshio Hirota; Christopher Nsereko; Takuya Okada; Bernard N Kanoi; Kohhei Tetsutani; Nobuko Arisue; Sawako Itagaki; Takahiro Tougan; Ken J Ishii; Shigeharu Ueda; Thomas G Egwang; Toshihiro Horii
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more
  22 in total

1.  Recombinase Polymerase Amplification and Lateral Flow Assay for Ultrasensitive Detection of Low-Density Plasmodium falciparum Infection from Controlled Human Malaria Infection Studies and Naturally Acquired Infections.

Authors:  Albert Lalremruata; The Trong Nguyen; Matthew B B McCall; Ghyslain Mombo-Ngoma; Selidji T Agnandji; Ayôla A Adegnika; Bertrand Lell; Michael Ramharter; Stephen L Hoffman; Peter G Kremsner; Benjamin Mordmüller
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

2.  Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults.

Authors:  Odilon Nouatin; Ulysse Ateba Ngoa; Javier Ibáñez; Jean Claude Dejon-Agobe; Benjamin Mordmüller; Jean Ronald Edoa; Fabrice Mougeni; Sina Brückner; Aurore Bouyoukou Hounkpatin; Meral Esen; Michael Theisen; Kabirou Moutairou; Stephen L Hoffman; Saadou Issifou; Adrian J F Luty; Marguerite M Loembe; Selidji Todagbé Agnandji; Bertrand Lell; Peter G Kremsner; Ayôla Akim Adegnika
Journal:  Vaccine       Date:  2020-05-05       Impact factor: 3.641

3.  Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults.

Authors:  Matthew B Laurens; Andrea A Berry; Mark A Travassos; Kathy Strauss; Matthew Adams; Biraj Shrestha; Tao Li; Abraham Eappen; Anita Manoj; Yonas Abebe; Tooba Murshedkar; Anusha Gunasekera; Thomas L Richie; Kirsten E Lyke; Christopher V Plowe; Jessie K Kennedy; Gail E Potter; Gregory A Deye; B K L Sim; Stephen L Hoffman
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

Review 4.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 5.  Systems biology of malaria explored with nonhuman primates.

Authors:  Mary R Galinski
Journal:  Malar J       Date:  2022-06-07       Impact factor: 3.469

6.  Meta-Analysis of Human Antibodies Against Plasmodium falciparum Variable Surface and Merozoite Stage Antigens.

Authors:  Eizo Takashima; Bernard N Kanoi; Hikaru Nagaoka; Masayuki Morita; Ifra Hassan; Nirianne M Q Palacpac; Thomas G Egwang; Toshihiro Horii; Jesse Gitaka; Takafumi Tsuboi
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 7.  Human unconventional T cells in Plasmodium falciparum infection.

Authors:  Mathias Schmaler; Nina Orlova-Fink; Tobias Rutishauser; Salim Abdulla; Claudia Daubenberger
Journal:  Semin Immunopathol       Date:  2020-02-19       Impact factor: 9.623

Review 8.  Decoding the complexities of human malaria through systems immunology.

Authors:  Tuan M Tran; Peter D Crompton
Journal:  Immunol Rev       Date:  2019-11-03       Impact factor: 10.983

Review 9.  Malaria vaccines: facing unknowns.

Authors:  Nirianne Marie Q Palacpac; Toshihiro Horii
Journal:  F1000Res       Date:  2020-04-27

10.  Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Authors:  Angela M Minassian; Sarah E Silk; Jordan R Barrett; Carolyn M Nielsen; Kazutoyo Miura; Ababacar Diouf; Carolin Loos; Jonathan K Fallon; Ashlin R Michell; Michael T White; Nick J Edwards; Ian D Poulton; Celia H Mitton; Ruth O Payne; Michael Marks; Hector Maxwell-Scott; Antonio Querol-Rubiera; Karen Bisnauthsing; Rahul Batra; Tatiana Ogrina; Nathan J Brendish; Yrene Themistocleous; Thomas A Rawlinson; Katherine J Ellis; Doris Quinkert; Megan Baker; Raquel Lopez Ramon; Fernando Ramos Lopez; Lea Barfod; Pedro M Folegatti; Daniel Silman; Mehreen Datoo; Iona J Taylor; Jing Jin; David Pulido; Alexander D Douglas; Willem A de Jongh; Robert Smith; Eleanor Berrie; Amy R Noe; Carter L Diggs; Lorraine A Soisson; Rebecca Ashfield; Saul N Faust; Anna L Goodman; Alison M Lawrie; Fay L Nugent; Galit Alter; Carole A Long; Simon J Draper
Journal:  Med (N Y)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.